Tazobactam is a potent inactivator of selected inhibitor-resistant class A β-lactamases

FEMS Microbiology Letters

Volumn 148, Issue 1, 1997, Pages 59-62

  Bonomo, R A ^a,b   Rudin, S A ^a   Shlaes, D M ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

inhibitor resistant lactamase; piperacillin; tazobactam

Indexed keywords

AMPICILLIN; BETA LACTAMASE; CLAVULANIC ACID; PIPERACILLIN; SULBACTAM; TAZOBACTAM; TICARCILLIN;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; ENZYME KINETICS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0031105398     PISSN: 03781097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1097(97)00013-X     Document Type: Article

References (14)

1. Blazquez, J., Baquero, M.R., Canton, R., Alos, I., and Baquero, F. (1993) Characteristics of a new TEM-type β-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate or Escherichia coli. Antimicrob. Agents Chemother. 37, 2059-2063.
2. Henquell, C., Chanal, C., Sirot, D., Labia, R., and Sirot, J. (1995) Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM β-lactamases from clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 39, 427-437.
3. Belaaouaj, A., Lapoumeroulie, C., Canica, M.M., Vedel, G., Nevot, P., Krishnamoorthy, R., and Paul, G. (1994) FEMS Microbiol. Lett. 120, 75-80.
4. Ambler, R.P., Coulson, A.F.W., Frere, J.M., Ghuysen, J.M., Joris, B., Forsman, M., Levesque, R.C., Tiraby, G., and Waley, S.G. (1991) A standard numbering scheme for the class A β-lactamases. Biochem. J. 276, 269-272.
5. Zhou, X.Y., Bordon, F., Sirot, D., Kitzis, M.-D., Gutmann, L. (1994) Emergence of clinical isolates of Esterichia coli producing TEM-1 derivatives or an OXA-1 β-lactamase conferring resistnce to β-lactamase inhibitors. Antimicrob. Agents Chemother. 38, 1085-1089.
6. Farzaneh, S., Chaibi, E.B., Peduzzi, J., Barthelemy, M., Labia, R., Blazquez, J., and Baquero, F. (1996) Implication of Ile-69 and Thr-182 residues in kinetic characteristics of IRT-3 (TEM-32) β-lactamase. Antimicrob. Agents Chemother. 40, 2434-2436.
7. Saves, I., Burlet-Schultz, O., Swaren, P., Lefevre, F., Masson, J.M., Prome, J.C., and Samama, J.P. (19??) The asparagine to aspartic acid substitution at position 276 of TEM-35 and TEM-36 is involved in β-lactamase resistance to clavulanic acid. J. Biol. Chem. 270, 18240-18245.
8. Bonomo, R.A., Currie-McCumber, C., and Shlaes, D.M. (1992) OHIO-1 beta-lactamase resistant to mechanism-based inactivators. FEMS Microbiol. Lett. 92, 79-82.
9. Bonomo, R.A., Dawes, C.G., Knox, J.R., and Shlaes, D.M. (1995) β-lactamase mutation far from the active site influence inhibitor binding. Biochim. Biophys. Acta 1247, 121-125.
10. Bonomo, R.A., Dawes, C.G., Knox, J.R., and Shlaes, D.M. (1995) Complementary role of positions 69 and 242 in β-lactam binding in OHIO-1 a class A β-lactamase. Biochim. Biophys. Acta 1247, 113-120.
11. National Committee for Clinical Laboratory Standards. (1993) National Committee for Clinical Laboratory Standards, 2nd edn., Villanova, PA.
12. Livermore, D.M. (1993) Determinants of the activity of β-lactamase inhibitor combinations. J. Antimicrob. Chemother. 31, Suppl. A, 9-21.
13. Zafarella, G., Manavathu, E.K., Lerner, S.A., and Mobashery, S. (1992) Elucidation fo the role of arginine-244 in the turnover processes of class A β-lactamases. Biochemistry 31, 3847-3852.
14. Payne, D.J., Cramp, R., Winstanley, D.J., and Knowles, D.J. (1994) Comparative activities of clavulanic acid, sulbactam and tazobactam against clinically important β-lactamases. Antimicrob. Agents Chemother. 38, 767-772.